By Professor Andrew David Carr

Journal articles

Winston A; Amin J; Marriott D; Mallon PW; Carr AD; Cooper DA; Emery S, 2006, 'Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy', HIV Medicine, 7, pp. 105 - 111

Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders J; Petoumenos K; Irvine K; Law MG; Grey PA; Finlayson R; Mcfarlane R; Kelleher AD; Carr AD; Cooper DA, 2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (Pulse)', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 42, pp. 192 - 202

Shulman N; Moyle G; Carr A; Boyle B, 2005, '12th Conference on Retroviruses and Opportunistic Infections (CROI). February 22-25, 2005; Boston, Massachusetts, USA', HIV Clinical Trials, 6, pp. 169 - 181, http://dx.doi.org/10.1310/EYBU-95QU-J9JM-JC1E

Behrens GMN; Grinspoon S; Carr A, 2005, 'Cardiovascular risk and body-fat abnormalities in HIV-infected adults [4] (multiple letters)', New England Journal of Medicine, 352, pp. 1721 - 1722, http://dx.doi.org/10.1056/NEJM200504213521620

Mallon PWG; Wand H; Law M; Miller J; Cooper DA; Carr A, 2005, 'Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia', Journal of Acquired Immune Deficiency Syndromes, 38, pp. 156 - 162, http://dx.doi.org/10.1097/01.qai.0000147527.64863.1a

Grinspoon S; Carr A, 2005, 'Cardiovascular risk and body-fat abnormalities in HIV-infected adults', New England Journal of Medicine, 352, pp. 48 - 62, http://dx.doi.org/10.1056/NEJMra041811

Petoumenos K; Ringland C; Australian HIV Observational Database , 2005, 'Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.', HIV Med, 6, pp. 155 - 163, http://dx.doi.org/10.1111/j.1468-1293.2005.00280.x

Winston A; Bloch MT; Carr AD; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387

Grinspoon SK; Carr AD, 2005, 'Cardiovascular risk and body-fat abnormalities in HIV-infected adults - Reply', New England Journal of Medicine, 352, pp. 1722 - 1722

Mallon PW; Miller JM; Kovacic JC; Kent-Hughes J; Norris RP; Samaras K; Feneley MP; Cooper DA; Carr AD, 2005, 'Changes in body composition and cardiovascular measures in hypercholesterolaemic HIV-infected men treated with pravastatin: a randomized, placebo-controlled study', Antiviral Therapy, 10, pp. L15 - L16

El-Sadr W; Mullin C; Carr AD; Gibert C; Rappoport C; Visnegarwala F; Grunfeld C; Raghavan S, 2005, 'Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort', HIV Medicine, 6, pp. 114 - 121

Carey DL; Wand HC; Martin A; Rothwell S; Emery S; Cooper DA; Carr AD, 2005, 'Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial', AIDS, 19, pp. 1325 - 1327

Sedwell R; Mallon PW; Duarte NL; Zaunders J; Kelleher AD; Cooper DA; Carr AD, 2005, 'Impaired mitochondrial function induced by NRTIs is only detectable in the monocyte (CD14(+)) subset of human PBMC', Antiviral Therapy, 10, pp. L44 - L45

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, 191, pp. 1686 - 1696

Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2005, 'Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors', Antiviral Therapy, 10, pp. L5 - L5

Kovacic JC; Martin A; Carey DL; Wand HC; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr AD, 2005, 'Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy', Antiviral Therapy, 10, pp. 135 - 143

Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Ganning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray JM; Gerlach W; Sun L; Penny R; Symonds GP; Carr AD; Cooper DA, 2005, 'Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients', Journal of Gene Medicine, 7, pp. 552 - 564

Grinspoon SK; Carr AD, 2005, 'Medical progress - Cardiovascular risk and body-fat abnormalities in HIV-infected adults', New England Journal of Medicine, 352, pp. 48 - 62

Mallon PW; Sedwell R; Unemori P; Kelleher AD; Cooper DA; Carr AD, 2005, 'Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy', Antiviral Therapy, 10, pp. M101 - M108

Lim H; Sedwell R; Duarte NL; Cooper DA; Kelleher AD; Carr AD; Mallon PW, 2005, 'Nucleoside reverse transcriptase inhibitor effects on adipocyte mitochondrial DNA quantity and quality in vitro', Antiviral Therapy, 10, pp. L41 - L42

Visnegarwala F; Raghavan S; Mullin C; Bartsch G; Wang J; Kotler DP; Gibert C; Shlay J; Grunfeld C; Carr AD; El-Sadr W, 2005, 'Sex differences in the associations of HIV disease characteristics and body composition in anti retroviral-naive persons', American Journal of Clinical Nutrition, 82, pp. 850 - 856

Winston A; McAllister J; Amin J; Cooper DA; Carr AD, 2005, 'The use of a triple nucleoside-nucleotide-regimen for occupational HIV post-exposure prophylaxis', HIV Medicine, 6, pp. 191 - 197

Calmy A; Pascual F; Ford N; Kulwichit W; Carr A, 2004, 'First-line and second-line antiretroviral therapy [7] (multiple letters)', Lancet, 364, pp. 329 - 330, http://dx.doi.org/10.1016/s0140-6736(04)16716-0

Ledergerber B; Lundgren JD; Sarah Walker A; Sabin C; Justice A; Reiss P; Mussini C; Wit F; d'Arminio Monforte A; Weber R; Fusco G; Staszewski S; Law M; Hogg R; Lampe F; John Gill M; Castelli F; Phillips AN; Rooney P; Taylor S; Couldwell D; Austin D; Block M; Clemons J; Finlayson R; Petoumenos K; Quan D; Smith D; O'Connor C; Gorton C; Allen D; Mulhall B; Mutimer K; Keeffe N; Cooper D; Carr A; Miller J; Pell C; Ellis D; Baker D; Kidd J; McFarlane R; Liang MT; Brown K; Huffam S; Savage J; Morgan S; Knibbs P; Sowden D; Walker A; Orth D; Lister G; Chuah J; Fankhauser W; Dickson B; Bradford D; Wilson C; Ree H; Magon H; Anderson J; Moore R; Russell D; McGovern G; McNair R; Bal J; Fairley K; Roth N; Eu B; Strecker S; Wood H; Mijch A; Hoy J; Pierce A; McCormack C; Watson K; Medland N; Daye J; Mallal S; French M; Skett J; Maxwel D; Cain A; Montroni M; Scalise G; Costantini A; Giacometti A; Tirelli U; Nasti G; Pastore G; Ladisa N; Perulli ML; Suter F; Arici C; Maggiolo F; Chiodo F; Gritti FM; Colangeli V; Fiorini C; Guerra L; Carosi G, 2004, 'Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes', Lancet, 364, pp. 51 - 62, http://dx.doi.org/10.1016/S0140-6736(04)16589-6

Cavalcanti RB; Raboud J; Kain KC; Walmsley S; Carr A; Wand H, 2004, 'Rosiglitazone for HIV-1 lipoatrophy [3] (multiple letters)', Lancet, 363, pp. 1828 - 1829, http://dx.doi.org/10.1016/S0140-6736(04)16318-6

Carr A; Workman C; Carey D; Rogers G; Martin A; Baker D; Wand H; Law M; Samaras K; Emery S; Cooper DA, 2004, 'No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial', Lancet, 363, pp. 429 - 438, http://dx.doi.org/10.1016/S0140-6736(04)15489-5

Martin A; Smith D; Carr A; Hoy J; Chuah J; Mallal S; Law M; Clements M; Cooper DA; Macrae K; James R; Mijch A; McCormack C; Baker D; McLeod H; Kidd J; McFarlane R; Vale R; Roth N; Wood H; Finlayson R; Bodsworth N; Wheatley D; Austin D; Bloch M; Frater A; Doong N; Hudson J; Anderson J; Patching J; Leung J; Lee W; Sharkey T; Wand H, 2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, 5, pp. 192 - 200, http://dx.doi.org/10.1310/0GU7-6X27-MMHE-5ALE

Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; Mcphee D; Mclachlan AJ; Gelder F; Lewin S; Liauw WS; Williams KM, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, 5, pp. 91 - 98

Ellis K; Grund B; Visnegarwala F; Mullin C; Miller C; Chesson C; El-Sadr W; Carr AD, 2004, 'Abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) measurements in HIV+ adults: influences of measurement site', Antiviral Therapy, 9, pp. L34 - L35

Carr AD, 2004, 'Antiretroviral therapy for previously untreated HIV-1-infected adults:2NN, or just one?', Lancet, 363, pp. 1248 - 1250

Hoy JF; Gahan M; Carr AD; Smith DE; Lewin S; Wesselingh S; Cooper DA, 2004, 'Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir', Journal of Infectious Diseases, 190, pp. 688 - 692

Mallon PW; Sedwell R; Unemori P; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, 9, pp. L56 - L56

Carr AD, 2004, 'First-line and second-line antiretroviral therapy - Author`s reply', Lancet, 364, pp. 330 - 330

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, 9, pp. L11 - L11

Mallon PW; Sedwell R; Unemori P; Merlin K; McGinley C; Ammaranond P; Peperias M; Rafferty M; Williams KM; Samaras K; Morey AL; Chisholm DJ; Kelleher AD; Cooper DA; Carr AD, 2004, 'Nucleoside reverse transcriptase inhibitors (NRTI) decrease adipocyte and monocyte mitochondrial (mt) messenger RNA transcription in the absence of changes in mtDNA or cell morphology', Antiviral Therapy, 9, pp. L56 - L57

Law MG; Cheng AJ; Cooper DA; Carr AD, 2004, 'Objective evaluation of HIV lipodystrophy case definition in a randomized 96 week clinical trial', Antiviral Therapy, 9, pp. L8 - L9

Martin A; Smith DE; Carr AD; Ringland C; Amin J; Emery S; Hoy JF; Workman C; Doong N; Freund J; Cooper DA, 2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, 18, pp. 1029 - 1036, http://www.medscape.com/viewarticle/474870

Carey DL; Workman C; Rogers GJ; Baker DA; Martin A; Wand HC; Emery S; Cooper DA; Carr AD, 2004, 'Rosiglitazone for HIV lipoatrophy: 84 weeks follow-up', Antiviral Therapy, 9, pp. L46 - L46

Carr AD; Wand HC, 2004, 'Rosiglitazone for HIV-1 Lipoatrophy', The Lancet, 363, pp. 1829 - 1829, http://dx.doi.org/10.1016/S0140-6736(04)16319-8

Carr AD; Wand HC, 2004, 'Rosiglitazone for HIV-1 lipoatrophy - Reply', Lancet, 363, pp. 1829 - 1829

Vanhems P; Voirin N; Philippe P; Hirschel B; Brassard J; Carr AD; Cooper DA; Perrin L; Allard R, 2004, 'The incubation period of acute retroviral syndrome as a multistepprocess - A parametric survival analysis', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 37, pp. 1529 - 1533

Friis-Møller N; Sabin CA; Weber R; d'Arminio Monforte A; El-Sadr WM; Reiss P; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Law MG; Kirk O; Phillips AN; Lundgren JD; Bartsch G; Dabis F; Houyez F; Loeliger E; Tressler R; Weller I; Sjøl A; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Meester R; Lavignolle V; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjær J; Hammer S; Neaton J; de Wolf F; van der Ven E; Zaheri S; Van Valkengoed I; Bronsveld W; Weigel H; Brinkman K; Frissen P; ten Veen J; Hillebrand M; van Dam P; Schieveld S; Mulder J; van Gorp E; Meenhorst P; van Eeden A; Danner S; Claessen F; Perenboom R; Eeftinck Schattenkerk JK; Godfried M; Lange J; Lowe S; van der Meer J; Nellen F; Pogany K; van der Poll T; Prins J; Ruys T; van der Valk M; Wit F; Richter C; van Leusen R; Vriesendorp R; Jeurissen F; Kauffmann R; Koger E; Bravenboer B; ten Napel C; Sprenger HG; Law G; ten Kate RW; Leemhuis M; Kroon F; Schippers E; Schrey G; van der Geest S; Verbon A; Koopmans P; Keuter M; Telgt D; van der Ven A; van der Ende M; Gyssens I; de Marie S; Juttmann J; van der Heul C; Schneider M; Borleffs J; Hoepelman I; Jaspers C; Matute A; Schurink C, 2003, 'Combination Antiretroviral Therapy and the Risk of Myocardial Infarction: The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group', New England Journal of Medicine, 349, pp. 1993 - 2003, http://dx.doi.org/10.1056/NEJMoa030218

Carr A, 2003, 'Cardiovascular risk factors in HIV-infected patients', Journal of Acquired Immune Deficiency Syndromes, 34, pp. S73 - S78, http://dx.doi.org/10.1097/00126334-200309011-00011

Carr A; Law M, 2003, 'An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score', Journal of Acquired Immune Deficiency Syndromes, 33, pp. 571 - 576, http://dx.doi.org/10.1097/00126334-200308150-00004

Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA, 2003, 'Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2', HIV Research & Clinical Practice, 4, pp. 252 - 261, http://dx.doi.org/10.1310/hct.2003.4.4.004

Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA; Kotsiou G; Norrito L; Dwyer D; Packham D; Fordham M; Garsia R; Baker D; Doong N; Quan D; Beveridge A; Genn W; Quin J; Mulholland J; Sowden D; Rawlinsen M; Rebic D; Street A; De Graaf B; Roney J; Bryant M; McCormack C; Hoy J; Shaw D; Ferguson W; Waddell R; Papanaoum K; French M; Mallal S; Scull N; Todhunter L; Jacobs S; James R; Foreman E; Chuah J; Watson A; Bowden F; Little B; Willington C; Habel P; Mills G; Morgan J; Thomas M; Porteous F; Franklin R; Reid M; Munro R; Sharkey T; Hudson J; Groves J; Blunt J; Clezy K; Lee W; Smith D; Cunningham P; Wood H, 2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: Ozcombo 1 and 2', HIV Clinical Trials, 4, pp. 252 - 261, http://dx.doi.org/10.1310/K2U9-QC2V-1Y3V-5DYF

Miller J; Carr A; Emery S; Law M; Mallal S; Baker D; Smith D; Kaldor J; Cooper DA, 2003, 'HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia', HIV Medicine, 4, pp. 293 - 301, http://dx.doi.org/10.1046/j.1468-1293.2003.00159.x

Vanhems P; Voirin N; Hirschel B; Cooper DA; Vizzard J; Carr A; Perrin L, 2003, 'Incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS', Journal of Acquired Immune Deficiency Syndromes, 32, pp. 542 - 544, http://dx.doi.org/10.1097/00126334-200304150-00012

Carr A, 2003, 'Lactic acidemia in infection with human immunodeficiency virus', Clinical Infectious Diseases, 36, pp. S96 - S100, http://dx.doi.org/10.1086/367565

Carr A; Emery S; Law M; Puls R; Lundgren JD; Powderly WG; Barr D; Cooper DA; Grinspoon S; Ioannidis J; Lewis R; Lichtenstein K; Murray J; Pizzuti D; Rozenbaum W; Schambelan M; Moore A; Miller J, 2003, 'An objective case definition of lipodystrophy in HIV-infected adults: A case-control study', Lancet, 361, pp. 726 - 735, http://dx.doi.org/10.1016/S0140-6736(03)12656-6

Back to profile page